Assessment of Clinical Efficacy and Tolerability of Terconazole 240-mg Vaginal Suppositories

Publisher Website
Google Scholar
Abstract
The present open study was performed to demonstrate the clinical effectiveness and tolerability of terconazole vaginal suppositories 240 mg. A total of 128 women (21 pregnant) with vaginal candidosis were treated with one vaginal suppository each. The mycological cure rates after 1 week were 76% of the pregnant women and 89% of the non-pregnant patients. 109 women returned for a second follow-up examination after 4 weeks. Cultures were negative for 13 out of 16 pregnant patients and for 84 (90%) of the 93 non-pregnant women. 1 week after application most patients were free of pruritus (72%) and burning (80%). Vaginal discharge had disappeared in 54% of the patients. Thus a single-dose treatment with a 240-mg vaginal suppository of terconazole seems to be an effective and well-tolerated treatment for vulvovaginal candidosis.

This publication has 0 references indexed in Scilit: